Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2022)

Inhibikase Therapeutics (IKT) has reported Interest Expenses for 6 consecutive years, with $31.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Interest Expenses changed N/A year-over-year to $31.7 million; the TTM figure through Dec 2025 stood at $31.7 million (changed N/A YoY), while the FY2025 annual figure was $31.7 million, up 1.8% from the prior year.
• Interest Expenses advanced to $31.7 million in Q4 2025 per IKT's latest filing, from $38322.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $31.7 million in Q4 2025 and bottomed at -$18460.0 in Q4 2021.
• Historically, Interest Expenses has averaged $2.2 million across 5 years, with a median of $32275.0 in 2023.
• Annual changes were most pronounced in 2021 — Interest Expenses sank 358.58% — and 2022, when it soared 44675.8%.
• Inhibikase Therapeutics' Interest Expenses stood at -$18460.0 in 2021, then surged by 480.81% to $70298.0 in 2022, then slumped by 54.09% to $32275.0 in 2023, then soared by 374.94% to $153288.0 in 2024, then soared by 20553.18% to $31.7 million in 2025.
• Business Quant data shows IKT's Interest Expenses at $31.7 million in Q4 2025, $38322.0 in Q2 2025, and $1872.0 in Q1 2025.